Fig. 5

The applications of in situ generation of CAR therapy in solid tumors. As for glioblastoma or brainstem gliomas, pCAR-laden nanomicelle or PBAE-based NPs with plasmid encoding CAR were utilized to produce CAR-M cells in situ via intracranial injection, respectively. As for hepatocellular carcinoma, CAR mRNA-LNPs were utilized to produce CAR-M cells in situ via intravenous injection. CAR-M cells could recognize tumor cells, present antigens to T cells, and further activate T cells and induce NK cell recruitment to play an anti-tumor role